3
Revista Matronas

Revista Matronas

DICIEMBRE 2021 N° 3 Volumen 9

Probiotics and vulvovaginal candidiasis

Section: Revisions

How to quote

Arredondo García E, Pozo Cano MD, Martínez García E, Álvarez Serrano MA. Probióticos y candidiasis vulvovaginal. Matronas Hoy 2021; 9(3):21-31.

Authors

1 Esther Arredondo García, 2 María Dolores Pozo Cano, 3 Encarnación Martínez García, 4 Mª Adelaida Álvarez Serrano

Position

1 Enfermera. Centro de Salud de las Arenas. Guecho (Vizcaya).2 Matrona. Doctora. Departamento de Enfermería. Universidad de Granada.3 Matrona. Doctora. Departamento de Enfermería. Universidad de Granada. Hospital de Guadix (Agencia Pública Hospital de Poniente).4 Enfermera. Doctora. Departamento de Enfermería. Universidad de Granada.

Contact email: pozocano@ugr.es

Abstract

Introduction: vulvovaginal candidiasis (VVC) is a health problem typically with an infectious origin. Treatment with antifungals and antibiotics is usually effective. However, some pathogens have been found to be resistant to traditional treatments. This has led to searching for new treatment options, such as probiotics.

Objectives: to identify the effect of probiotics on vulvovaginitis, as well as their efficacy in recurrent vulvovaginitis, and to compare their vaginal and oral routes of administration.
Methodology: for this bibliographic review, Pubmed, Cuiden, Cinahl and Scopus were used as databases. After applying inclusion criteria and an assessment, 14 articles were selected for said review.

Results and discussion: some Lactobacillus were good probiotic microorganisms, because they presented antifungal activity and were able to re-establish vaginal colonization, thus improving symptoms. It was suggested that probiotics could help to prevent and treat VVC. The majority of studies using oral administration showed optimal results; however, only two articles showed positive outcomes with the vaginal route of administration. The combination of probiotics with antifungal drugs was also studied for recurrent vulvovaginal candidiasis (RVVC), and the conclusion was that this joint therapy could be an effective combination.

Conclusion:  Lactobacillus are probiotic bacteria which colonize, recover and sustain the normal vaginal microbiota. Oral administration is considered more positive, based on previously published studies. Probiotics in combination with antifungal drugs can be an effective treatment for recurrence.

Keywords:

vulvovaginal candidiasis; probiotics; Lactobacillus; Candida albicans; antifungals; vaginitis

Versión en Español

Título:

Probióticos y candidiasis vulvovaginal

Artículo completo no disponible en este idioma / Full article is not available in this language

Bibliography

  1. Álvarez-Calatayud G, Suárez E, Rodríguez JM, Pérez-Moreno J. La microbiota en la mujer: aplicaciones clínicas de los probióticos. Nutrición Hospitalaria. [internet] 2015 [citado 15 nov 2021]; 32(1):56-61. Disponible en: http://www.aulamedica.es/nh/pdf/9481.pdf
  2. Castro A, González M, Tarín JJ, Cano A. Papel de los probióticos en Obstetricia y Ginecología. Nutrición Hospitalaria. [internet] 2015 [citado 15 nov 2021]; 31(1):26-9. Disponible en: https://www.redalyc.org/pdf/3092/309238517004.pdf
  3. Olveira Fuster G, González-Molero I. Probióticos y prebióticos en la práctica clínica. Nutrición Hospitalaria. [internet] 2007 [citado 15 nov 2021]; 22(2):26-34. Disponible en: http://scielo.isciii.es/pdf/nh/v22s2/fisiologia4.pdf
  4. Cancelo Hidalgo MJ, Beltrán Vaquero D, Calaf Alsina J, Campillo Arias-Camisón F, Cano Sánchez A, Guerra Guirao JA, Neyro Bilbao JL. Protocolo Sociedad Española de Ginecología y Obstetricia de diagnóstico y tratamiento de las infecciones vulvovaginales. Protocolo actualizado en 2012. Progresos de Obstetricia y Ginecología. [internet] 2013 [citado 15 nov 2021]; 56(5):278-84. Disponible en: https://www.elsevier.es/es-revista-progresos-obstetricia-ginecologia-151-pdf- S030450131300006X
  5. Tauany Andrade J, Fantini de Figueiredo G, Ferreira Cruz L, Eliza de Morais S, Ferreira Souza CD, Horta Pinto F.C, Siqueira Ferreira JM, De Freitas Araújo MG. Efficacy of curcumin in the treatment of experimental vulvovaginal candidiasis. Revista Iberoamericana de Micología. [internet] 2019 [citado 15 nov 2021]; 36(4):192-9. Disponible en: https://reader.elsevier.com/reader/sd/pii/S1130140619300294?token=E3CE488 48312A049BD311F7E318CC9C959757A9D0763966E77857906E81854D778D 7772F2BD432EE7DE4548E72544423
  6. Yazdanparast SA, Khodavaisy S, Fakhim H, Shokohi T, Haghani I, Nabili M, et al. Molecular characterization of highly susceptible candida africana from vulvovaginal candidiasis. Mycopathologia. [internet] 2015 [citado 15 nov 2021]; 180:317-23. Disponible en: https://link.springer.com/content/pdf/10.1007%2Fs11046-015-9924-z.pdf
  7. Hamma NM, El Badawy NE, Nasr AM, Ghramh HA, Al Kady LM. Mannose-binding lectin gene polymorphism and its association with susceptibility to recurrent vulvovaginal candidiasis. BioMed Research International. [internet] 2018 [citado 15 nov 2021]. Disponible en: https://www.researchgate.net/profile/ Nissreen_Elbadawy/publication/32424477 4_MannoseBinding_Lectin_Gene_Polymorphism_and_Its_Association_with_Su sceptibility_to_Recurrent_Vulvovaginal_Candidiasis/links/5cfda70692851c874c 5b511d/Mannose-Binding-Lectin-Gene-Polymorphism-and-Its-Association-with- Susceptibility-to-Recurrent-Vulvovaginal-Candidiasis.pdf
  8. Barrenetxea Ziarrusta G. Vulvovaginitis candidiásica. Rev Iberoam Micol. [internet] 2002 [citado 15 nov 2021]; 19:22-4. Disponible en: http://www.reviberoammicol.com/2002-19/022024.pdf
  9. Tena González JA, San Juan P, Herráiz Esteban N, De Castellar Sansó R, Tort Sánchez G. Boric acid and probiotics in bacterial and fungal vulvovaginitis as an effective therapeutic option. Prog Obstet Ginecol. [internet] 2019 [citado 15 nov 2021]; 62(3):221-9. Disponible en: https://sego.es/documentos/progresos/v62-2019/n3/04-TO_acido-borico-ing.pdf
  10. Er S, Istanbullu Tosun A, Arik G, Kivanç M. Anticandidal activities of lactic acid bacteria isolated from the vagina. Turk J Med Sci. [internet] 2019 [citado 15 nov 2021]; 49(1):375-83. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30761844
  11. Deidda F, Amoruso A, Nicola S, Graziano T, Pane M, Allesina S, et al. The in vitro effectiveness of Lactobacillus fermentum against different candida species compared with broadly used azoles. J Clin Gastroenterol. [internet] 2016 [citado 15 nov 2021]; 50(2). Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27741168
  12. Vladareanu R, Mihu D, Mitran M, Mehedintu C, Boiangiu A, Manolache M, et al. New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double- blind placebo controlled study. Eur Rev Med Pharmacol Sci. [internet] 2018 [citado 15 nov 2021]; 22(1):262-7. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29364495
  13. Santamaría Orleans A, De la Iglesia Arnaez R, Blanco-Soler Palacios-Pelletier C, Tena González JA. Estudio PROBIT sobre la utilización de probióticos orales en las infecciones vaginales. Nutr Clin Diet Hosp. [internet] 2017 [citado 15 nov 2021]; 37(4):60-8. Disponible en: https://revista.nutricion.org/PDF/ORLEANS.pdf
  14. Mezzasalma V, Manfrini E, Ferri E, Boccarusso M, Di Gennaro, Schiano I, Michelotti A, et al. Orally administered multispecies probiotic formulations to prevent urogenital infections: a randomized placebo-controlled pilot study. Arch Gynecol Obstet. [internet] 2017 [citado 15 nov 2021]; 295(1):163-72. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27826653
  15. Vicariotto F, Del Piano M, Mogna G. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. [internet] 2012 [citado 15 nov 2021]; 46:73-80. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22955364
  16. De Seta F, Parazzini F, De Leo R, Banco R, Maso GP, De Santo D, et al. Lactobacillus plantarum P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study. Eur J Obstet Gynecol Reprod Biol. [internet] 2014 [citado 15 nov 2021]; 182:136-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25305660
  17. Davar R, Nokhostin F, Eftekhar M, Sekhavat L, Bashiri Zadeh M, Shamsi F. Comparing the recuerrence of vulvovaginal candidiasis in patients undergoing prophylactic treatment with probiotic and placebo during the 6 months. Probiotics Antimicrob Proteins. [internet] 2016 [citado 15 nov 2021]; 8(3):130-3. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27206514
  18. Shen J, Su M. Features of vaginal bacteria community in women with recurrent vulvovaginal candidiasis. Journal of Reproduction and Contraception. [internet] 2015 [citado 15 nov 2021]; 26(4):229-38. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1001784416300062
  19. Murina F, Graziottin A, Vicariotto F, De Seta F. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a slow release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis? A clinical study. J Clin Gastroenterol. [internet] 2014 [citado 15 nov 2021]; 48(1):102-5. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25291115
  20. Palacios S, Espadaler J, Fernández-Moya JM, Prieto C, Salas N. Is it posible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504). Eur J Clin Microbiol Infect Dis. [internet] 2016 [citado 15 nov 2021]; 35(10):1701-8. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27393491
  21. Pendharkar S, Brandsborg E, Hammarström L, Marcotte y Larsson PG. Vaginal colonization by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection. BMC Infect Dis. [internet] 2015 [citado 15 nov 2021]; 15:255. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26137971
  22. Russo R, Superti F, Karadja E, De Seta F. Randomised clinical trial in women with recurrent vulvovaginal candidiasis: efficacy of probiotics and lactoferrin as maintenance treatment. Mycoses. [internet] 2019 [citado 15 nov 2021]; 62(4):328-35. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30565745
  23. Williams NT. Probiotics. Am J Health Syst Pharm. [internet] 2010 [citado 15 nov 2021]; 67(6):449-58. Disponible en: https://pubmed.ncbi.nlm.nih.gov/20208051/